---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009776"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T11:09:16.278114+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia reports NTLA-2002 Phase 1 data: 95% reduction in HAE attacks; 9/10 attack-free

## Summary
- Single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate across all 10 patients.
- Nine of 10 patients remained completely attack-free following the 16-week primary observation period.
- All 6 patients who discontinued long-term prophylaxis reported no attacks since stopping.
- NTLA-2002 well-tolerated; most common adverse events were mild infusion reactions and fatigue.
- Global pivotal Phase 3 study planned for H2 2024 subject to regulatory feedback.

## SEC filing metadata
- accession: 0000950170-24-009776
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/0000950170-24-009776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024009776/ntla-20240131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009776
- JSON: https://secwatch.observer/filing/0000950170-24-009776.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.